Literature DB >> 26407508

The burden of Chagas disease: estimates and challenges.

Jeffrey D Stanaway1, Gregory Roth2.   

Abstract

Chagas disease, caused by infection with the protozoa Trypanosoma cruzi is transmitted most often by Triatominae insect vectors, but also through blood transfusion, organ transplant, and congenital transmission. Between 5 and 18 million people are currently infected and the infection is estimated to cause more than 10,000 deaths annually. The disease has 3 phases: acute, indeterminate, and chronic. The acute phase immediately follows infection. It is typically asymptomatic but produces fever and malaise in up to 5% of people. The indeterminate phase is asymptomatic. More than one-half of those infected will remain in this phase for life and never experience long-term sequelae. After a decade or more, 20% to 30% of people will experience chronic cardiovascular Chagas disease with sequelae including heart failure, arrhythmias, and thromboembolism. Another 15% to 20% will experience chronic digestive sequela including megaesophagus and megacolon. A complete accounting of the burden of Chagas disease requires estimating the prevalence of the infection, the prevalence of each of its sequelae among those with the infection, and the number of deaths attributable to the infection. Attempts to estimate Chagas disease prevalence are complicated by several challenges imposed by the disease's extreme spatial heterogeneity, quickly evolving temporal trends, the decades-long lag between infection and symptomatic disease, biased prevalence data, incomplete recognition of Chagas-attributable deaths, limited data on sequela, and a near total absence of data outside of endemic countries. Even though researchers have found methodological approaches to dealing with these challenges, there is a need for better data.
Copyright © 2015 World Heart Federation (Geneva). Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26407508     DOI: 10.1016/j.gheart.2015.06.001

Source DB:  PubMed          Journal:  Glob Heart


  49 in total

Review 1.  Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.

Authors:  V Balouz; F Agüero; C A Buscaglia
Journal:  Adv Parasitol       Date:  2016-11-14       Impact factor: 3.870

2.  Gold Nanoshells-Based Lateral Flow Assay for the Detection of Chagas Disease at the Point-of-Care.

Authors:  Melisa Medina-Rivera; Washington B Cárdenas; David Erickson; Saurabh Mehta
Journal:  Am J Trop Med Hyg       Date:  2022-06-27       Impact factor: 3.707

3.  Physician Knowledge, Attitudes, and Practices Related to Chagas Disease in Tabasco, Mexico.

Authors:  Brandon A Berger; Allison H Bartlett; Ricardo Jiménez-Hernández; Esmelin Trinidad Vázquez; Norma Galindo-Sevilla
Journal:  Am J Trop Med Hyg       Date:  2018-04-19       Impact factor: 2.345

Review 4.  Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.

Authors:  Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina
Journal:  Pathogens       Date:  2021-04-22

5.  Development of a PCR Assay to Detect Low Level Trypanosoma cruzi in Blood Specimens Collected with PAXgene Blood DNA Tubes for Clinical Trials Treating Chagas Disease.

Authors:  Bo Wei; Lei Chen; Miho Kibukawa; John Kang; Hetty Waskin; Matthew Marton
Journal:  PLoS Negl Trop Dis       Date:  2016-12-01

6.  4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.

Authors:  Claudia Magalhaes Calvet; Jun Yong Choi; Diane Thomas; Brian Suzuki; Ken Hirata; Sharon Lostracco-Johnson; Liliane Batista de Mesquita; Alanderson Nogueira; Marcelo Meuser-Batista; Tatiana Araujo Silva; Jair Lage Siqueira-Neto; William R Roush; Mirian Claudia de Souza Pereira; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2017-12-27

7.  Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress.

Authors:  Marcos Lopez; Herbert B Tanowitz; Nisha J Garg
Journal:  Curr Clin Microbiol Rep       Date:  2018-01-19

8.  Do the new triatomine species pose new challenges or strategies for monitoring Chagas disease? An overview from 1979-2021.

Authors:  Jane Costa; Carolina Dale; Cleber Galvão; Carlos Eduardo Almeida; Jean Pierre Dujardin
Journal:  Mem Inst Oswaldo Cruz       Date:  2021-05-31       Impact factor: 2.743

Review 9.  A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease.

Authors:  Cody J Malone; Immaculate Nevis; Eduardo Fernández; Ana Sanchez
Journal:  Trop Med Infect Dis       Date:  2021-07-12

10.  Psychosocial burden of neglected tropical diseases in eastern Colombia: an explorative qualitative study in persons affected by leprosy, cutaneous leishmaniasis and Chagas disease.

Authors:  Robin van Wijk; Lena van Selm; Martha C Barbosa; Wim H van Brakel; Mitzi Waltz; Karl Philipp Puchner
Journal:  Glob Ment Health (Camb)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.